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Cardiac diseaseroles in all biological processes, the ﬁnely tuned equilibrium between their
synthesis and degradation regulates cellular homeostasis. Controlling the quality of proteome informational
content is essential for cell survival and function. After initial synthesis, membrane and secretory proteins are
modiﬁed, folded, and assembled in the endoplasmic reticulum, whereas other proteins are synthesized and
processed in the cytosol. Cells have different protein quality control systems, the molecular chaperones,
which help protein folding and stabilization, and the ubiquitin–proteasome system (UPS) and lysosomes,
which degrade proteins. It has generally been assumed that UPS and lysosomes are regulated independently
and serve distinct functions. The UPS degrades both cytosolic, nuclear proteins, and myoﬁbrillar proteins,
whereas the lysosomes degrade most membrane and extracellular proteins by endocytosis as well as
cytosolic proteins and organelles via autophagy. Over the last two decades, the UPS has been increasingly
recognized as a major system in several biological processes including cell proliferation, adaptation to stress
and cell death. More recently, activation or impairment of the UPS has been reported in cardiac disease and
recent evidence indicate that autophagy is a key mechanism to maintain cardiac structure and function. This
review mainly focuses on the UPS and its various components in healthy and diseased heart, but also
summarizes recent data suggesting parallel activation of the UPS and autophagy in cardiac disease.
© 2008 Elsevier B.V. All rights reserved.1. The cardiac ubiquitin–proteasome systemThe ubiquitin–proteasome system (UPS) is an ATP-dependent
proteolytic system that requires the polyubiquitination of a protein
intended for degradation by the 26S proteasome [1]. While it is known
that the speciﬁcity of the system lies in the E3 ubiquitin ligases, recent
evidence indicate that the cardiac 20S proteasome has functional
partners involved in the β-adrenergic stimulation, underlying the
importance of the UPS and its cardiac-speciﬁc components in the heart.
1.1. Protein ubiquitination
Protein ubiquitination consists of the covalent linkage of ubiquitin
molecules to one or more lysine residues of a protein. In general,
degradation by the UPS requires the “canonical” ubiquitination,
characterized by the covalent attachment of one or more chains of
polyubiquitin linked through their lysine 48 (K48) to the targeted
protein (Fig. 1). However, ubiquitination can form ubiquitin chainsnd Clinical Pharmacology and
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l rights reserved.through linkage of other lysine residues (e.g. lysine 63, K63) and
represents “non-canonical” ubiquitination (Fig. 1). In this case, the
K63 chains are more extended and elongated than the more compact
K48 chains (Fig. 1). Polyubiquitination through K63 is involved in
other mechanisms such as protein localization and cellular signaling.
In addition, monoubiquitination exists and is involved in the
regulation of protein function or localization (Fig. 1). The process of
ubiquitination involves the concerted action of ubiquitin enzymes
composed of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugat-
ing enzymes) and E3 (ubiquitin ligases). Sometimes, efﬁcient multi-
ubiquitination requires an additional conjugation factor, named E4 [2].
While there is a single E1, about ﬁfty E2 and more than hundred E3
enzymes have been described. The E3 ubiquitin ligases confer substrate
speciﬁcity to the whole system. They are often grouped in two different
categories depending on the presence of either an HECT (homologous
to E6-AP carboxy-terminus) or a RING (really interesting new gene)
ﬁnger as catalytic domain [3,4]. It is worth to note that ubiquitination
has important roles independent of the proteasome such as regulation
of the activity of transcription factors, regulation of gene transcription
and autophagy, and that the same target can be mono, multi and
polyubiquitinated [5,6]. Up to now, several hundred distinct E3
ubiquitin ligases have been identiﬁed, but only few are muscle-speciﬁc
and are presented here (Fig. 2 and Table 1).
Fig. 1. Models of ubiquitin chain formation. Ubiquitin contains seven Lys (K) residues, which can all be used for the formation of ubiquitin chains. (A) Chains linked via K48
(“canonical” ubiquitination) are recognized for UPS-mediated degradation of the target proteins. (B) The more extended chains linked via K63 (“non-canonical” ubiquitination) are
implicated in DNA repair and activation of protein kinases. (C) Addition of a single ubiquitin at any K residue can result in a change in localization, transcriptional regulation
and endocytosis.
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Atrogin-1 (Atrophy gene 1), also known asMAFbx (Muscle Atrophy
F-box), was ﬁrst identiﬁed in 2001 as a muscle-speciﬁc E3 ubiquitin
ligase highly expressed inmuscle atrophy [7,8]. Atrogin-1 contains a F-
box motif [9,10], which is a protein–protein interaction domain found
in proteins that are component of the SCF (skp1, cullin, F-box protein)
ubiquitin ligase complex, a subgroup of the RING ﬁnger E3 ubiquitin
ligase (Fig. 2F) [11]. Thus, atrogin-1 per se has no ligase activity but
acts as a bridge between the substrate and the enzymatic complex.
Other important domains were found along the protein: i) a nuclear
localization signal (NLS), which suggests that atrogin-1 could also be
involved in the regulation of muscle-speciﬁc transcription factors or
other nuclear proteins involved in muscle growth [7], and ii) a PDZ
domain [12] at the C-terminus, which probably mediates the
interaction with the different substrates. However, leucine-rich
regions and WD40 repeats, which are known to be the domains for
interaction with protein substrate in other F-box proteins, are not
present in atrogin-1.
Northern blot analysis showed that atrogin-1 expression is
restricted to the cardiac and skeletal muscles inmice, rats and humans
[7,8]. After adenoviral gene transfer in cardiomyocytes atrogin-1 was
found in the Z-line of the sarcomere, where it colocalizes with α-
actinin and calcineurin [13]. Moreover, atrogin-1 decreases the level of
calcineurin and participates in a SCFatrogin-1 complex to ubiquitinate
calcineurin in vitro [13]. The expression of atrogin-1 is under the
control of the FoxO (Forkhead box O) family of transcription factors
[14,15], and therefore linked to the network of PI3K/Akt signaling
pathway involved in the physiological hypertrophic response [16].
Recently, it was shown that FoxO1 and FoxO3 are substrates for
atrogin-1-mediated “non-canonical” ubiquitination through K63
linkage chains [17]. The presence of K63 chains is known to modulate
protein function [18], and indeed K63-mediated polyubiquitination of
FoxO1 and FoxO3 enhances their transcriptional activity rather than
their degradation [17]. Another substrate for atrogin-1-mediated
degradation is MyoD, a transcription factor involved in muscle
development and differentiation [19]. No cardiac transcription factors
are known to be targeted by atrogin-1 for degradation yet.
1.1.2. Muscle RING ﬁnger proteins
Muscle RING ﬁnger proteins (MuRF1, MuRF2 and MuRF3) are
encoded by distinct genes but share high sequence homology. They
are composed of few conserved structural domains: i) the RING ﬁngerdomain, a zinc ﬁnger motif at the N-terminal sequence composed of
cysteine and histidine residues, which plays a critical role for the
ubiquitin ligase activity [20], ii) the B-box domain, a second zinc ﬁnger
motif for which no speciﬁc function has been yet attributed, and iii)
the coiled-coil domainmainly involved in protein–protein interaction,
which therefore allows homo or heterodimerization (Fig. 2C). Proteins
characterized by these three domains are also called RBCC or TRIM
proteins [21,22]. Moreover, there is an additional highly conserved
motif called MFC-motif (MURF-family conserved domain) between
the RING ﬁnger and the B-box, which is exclusively found in MuRF
proteins.
As for atrogin-1, the tissue distribution of MuRF transcripts is
restricted to striated muscles, and MuRF1 expression is up-regulated
during skeletal muscle atrophy [8,23,24]. MuRF1 is mainly located in
the M-band of the sarcomere, where it interacts with titin, but also at
the Z-line and in the nucleus [24,25]. MuRF2 is mainly diffused in the
cytoplasm, where it colocalizes with microtubules and intermediate
ﬁlaments. It can associate with the sarcomeric M-line, where it also
interacts with titin, and can shuttle between the cytoplasm and the
nucleus [26,27]. MuRF3 is associated with microtubules and also
located at the Z-line of the sarcomere [23]. Yeast-two hybrid screens of
a cardiac cDNA library with MuRF1 or MuRF2 baits identiﬁed
sarcomeric proteins, transcription and translation factors, ribosomal
components and proteins involved in mitochondrial energy metabo-
lism as binding partners [28–30]. Furthermore, the E3 ligase activity of
MuRF1 was shown for cardiac troponin I (TnI), protein kinase C
epsilon (PKCɛ), and muscle creatine kinase (M-CK) [29,31,32]. The
identiﬁcation of M-CK as a target for MuRF1-mediated degradation
places MuRF1 under a new light since it could represent the connector
between protein turnover and muscle metabolism [32]. Recently, four
and a half LIM protein 2 (FHL2) and γ-ﬁlamin have been shown to be
targeted by MuRF3 for proteasome-mediated degradation [33].
Interestingly, whereas MuRF1 has been shown to be a E3 ligase of
both fast and slow/β-myosin heavy chain (β-MHC) in C2C12myotubes
treatedwith dexamethasone [34], bothMuRF1 andMuRF3 are needed
together for ubiquitination and degradation of MHC in vivo [35]. To
date, no substrate for MuRF2-mediated degradation has been
described.
1.1.3. Other E3 ubiquitin ligases
Although atrogin-1 and MuRF proteins are the best characterized
muscle-speciﬁc E3 ubiquitin ligases, there are others which are worth
Fig. 2. Mechanism of action of muscle-speciﬁc E3 ligases on their substrates. (A to C) CHIP, Mdm2 and MuRF1 are monomeric E3 ubiquitin ligases that mediate the transfer of
ubiquitin molecules from the E2 conjugating-enzyme to the target proteins (in green). The interaction with the E2 takes place at either the U-box domain (CHIP) or the RING ﬁnger
domain (Mdm2 and MuRF1). (D) Ozz participates in the multi-subunit VCB complex for ubiquitination of phosphorylated (P) β-catenin. Ozz interacts through the SOCS domain with
the adaptor protein elongin B/C which, together with cullin1 and Roc1, forms a E3 ligase complex, and therefore offers a platform for interactionwith the E2 conjugating-enzyme. (E)
The HECT-E3 ligase Nedd4-like forms an intermediate thioester-bond with ubiquitin and interacts through the WW domains with the conserved PY domain of the target proteins
(voltage-gated channels). (F) Atrogin-1 contains a F-box motif but no ligase activity per se. It acts as a bridge between the enzymatic complex of the SCF (skp1, cullin, F-box protein)
and the substrate. Peptides correspond to the digested substrates.
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interacting protein) is highly expressed in the heart and has dual
function as a cochaperone and E3 ubiquitin ligase. CHIP plays a very
important role in the regulation of protein quality control [36,37]. On
the one hand, CHIP interacts with the chaperones Hsp70 and Hsp90,
and increases refolding rates of stress-damaged proteins. On the other
hand, it promotes proteasome-mediated degradation of irreversibly
damaged proteins (Fig. 2A). Moreover, CHIP not only enhances Hsp70
induction during acute stress, but also mediates Hsp70 turnover
during the stress recovery process [38,39]. In addition, CHIP alsodegrades p53 [40]. The catalytic domain for the ligase activity is a U-
box, a RING ﬁnger-like domainwithout Zn-coordinating residues [41].
Several transcription factors are regulated by ubiquitination and by
UPS-mediated degradation. Therefore, cell biology can be markedly
affected by differential gene expression as a consequence of
ubiquitination and degradation. One example is the altered gene
expression mediated by the hypoxia-inducible transcription factor 1a
(HIF-1α) and HIF-2α in response to hypoxia. The HIFs are basic helix–
loop–helix transcription factors that regulate the expression of a wide
variety of genes involved in a multitude of biological functions,
Table 1
Muscle-speciﬁc E3 ubiquitin ligases
E3 ubiquitin ligase Type Substrate References
Atrogin-1 (MAFbx) RING ﬁnger, SCF
complex
CnA, MyoD, FoxO1, FoxO3 [13,17,19]
MuRF1 (Trim63) RING ﬁnger,
single subunit
cTnI, PKCɛ, M-CK, β-MHC [29,31,32,35]
MuRF3 (Trim54) RING ﬁnger,
single subunit
FHL2, γ-ﬁlamin, β-MHC [33,35]
CHIP U-box misfolded proteins, Hsp70,
GATA4
[39,130]
Mdm2 RING ﬁnger,
single subunit
p53, β-arrestin2, Tcap [44–46,197]
Ozz RING ﬁnger,
VCB complex
β-catenin [47]
Nedd4-like HECT domain Nav1.5, KCNQ1 [50,51]
Trim32 RING ﬁnger Actin [52]
Abbreviations used are: β-MHC, β-myosin heavy chain; CHIP, carboxyl-terminus of
Hsp70-interacting protein; CnA, calcineurin; cTnI, cardiac troponin I; FHL2, four and a
half LIM protein-2; FoxO, Forkhead box O; GATA4, GATA binding protein 4; Hsp70, heat
shock protein 70; KCNQ1, voltage-gated potassium channel; MAFbx, Muscle Atrophy
F-box; M-CK, muscle creatine kinase; Mdm2, murine double minute 2; MyoD,myogenic
differentiation factor; MuRF, muscle RING ﬁnger protein; Nedd4, neuronal precursor
cell expressed developmentally down-regulated; Nav1.5, voltage-gated sodium
channel; p53, protein 53; PKC, protein kinase C; Tcap, titin-cap, telethonin; Trim,
TRIpartite interaction motif.
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major level of HIF-1α regulation is post-translational and involved the
Hippel–Lindau protein (VHL), which is a major subunit in an E3
ubiquitin ligase complex, and the UPS [42]. Under normoxic condi-
tions, HIF-1α undergoes prolyl hydroxylation that promotes VHL
binding and subsequent ubiquitination of HIF [43]. Another example is
the transcription factor p53, which is targeted by Mdm2 (murine
double minute 2), another interesting RING ﬁnger E3 ligase, for
proteasome-mediated degradation (Fig. 2B). Mdm2-mediated ubiqui-
tination of p53 results in inactivation of its transcriptional activity,
nuclear export and degradation [44]. Upon β2-adrenergic stimulation,
Mdm2 ubiquitinates β-arrestin that induces rapid internalization of
the β2-adrenergic receptors [45]. In addition, Mdm2 interacts with
and down-regulates the sarcomeric protein Tcap (telethonin) through
the proteasomal pathway, but in an ubiquitin-independent manner,
yet not completely described [46].
Ozz is another muscle-speciﬁc E3 ligase for the membrane-bound
β-catenin (Fig. 2D) [47]. It is a member of the suppressor of cytokine
signaling (SOCS) family, and, similarly to F-box proteins, acts as a
bridge between the substrate and the cullin, elonginB/C and Rbx1
SCF-like complex [48]. Ozz is also involved in maintaining the
organization and alignment of sarcomeres and its inhibition or
knock-down leads to accumulation of β-catenin causing myoﬁbrillar
abnormalities [47].
Recent studies pointed out that the Nedd4 (neuronal precursor cell
expressed developmentally down-regulated)-like family of HECT-
type E3 ligases are very important in the regulation of cardiac
voltage-gated sodium (Nav1.5) and potassium (KCNQ1) channels (Fig.
2E). Nedd4-like proteins contain two to four WW domains (protein–
protein interaction), which interact with the conserved PY-motif
(xPPxY) of target proteins [49]. PY-motifs are found at the C-terminus
of the channels and mediate the interaction with and ubiquitination
by the Nedd4-like ubiquitin ligase. This induces internalization and
consequent decrease in surface channel density [50,51].
The lastly identiﬁed muscle-speciﬁc E3 ligase is Trim32. As the
MuRF proteins, Trim32 belongs to the TRIM protein family and is
expressed primarily in skeletal muscle. It has been shown that
Trim32 controls muscle protein turnover. A recent study demon-
strated that Trim32 has E3 ubiquitin ligase activity and binds to the
S1 and S2 region of myosin and ubiquitinates actin in vitro [52]. The
involvement of Trim32 as an E3 ligase in the heart has not been
described yet.1.2. The cardiac proteasome
The eukaryotic 26S proteasome (named on the basis of its
sedimentation coefﬁcient) is a multicatalytic protein complex that is
composed of two multi-subunit subcomplexes, the 670 kDa 20S
proteasome and the 900 kDa 19S regulatory complex (Fig. 3) [53]. The
19S regulatory complex binds to either or both ends of the 20S
proteasome resulting in a 26S proteasome with a molecular mass of
1500 kDa or 2400 kDa, respectively. The function of the 19S regulatory
complex is to recognize, bind, deubiquitinate and unfold polyubiqui-
tinated proteins and to regulate the opening of the 20S core to channel
the unfolded proteins into the 20S proteasome. The unfolded proteins
are then degraded by peptidases in the cavity of the 20S proteasome.
1.2.1. The 20S proteasome
The 20S proteasome represents the proteolytic core of the 26S
proteasome. It is a barrel-shaped protein complex containing 28
subunits consisting of two copies of fourteen different proteins.
According to the nomenclature of Baumeister et al. [54] the subunits
are named α1–α7 and β1–β7 (Fig. 3). To reach the proteolytic core
of the β-rings, proteins have to pass through a narrow, gated pore,
which is formed by the seven subunits α1–α7 of the α-rings [55].
The N-terminal peptides of the α-subunits constitute a physical
barrier and prevent the access of the unfolded proteins into the
proteolytic core of the β-rings, when the 26S proteasome is in a
nonactive state [55]. After activation of the 26S proteasome by
binding of the 19S regulatory complex to the α-ring of the 20S
proteasome, the α-subunits rearrange and the occlusion by their
peptides is abolished resulting in the free entrance of the proteins
into the proteolytic core.
The proteolytic activity of the 20S proteasome resides on the inner
surface of the β-rings (Fig. 3). The unfolded proteins are degraded by
three major peptidase activities: the chymotrypsin-like, the trypsin-
like and the caspase-like (or post-glutamyl peptide hydrolase)
activities, which reside in the β5-, β2- and β1-subunit of each β-
ring, respectively. The peptidase of the β1-subunit preferentially
cleaves after acidic amino acids, the peptidase of the β2-subunit after
basic amino acids and the peptidase of the β5-subunit after
hydrophobic amino acids. All three peptidases exhibit the same
catalytic mechanism, inwhich the N-terminal threonine residue is the
active nucleophile [54,56]. It is possible to measure the proteolytic
activities in vitro using ﬂuorogenic substrates, which are small
peptides containing 3–4 amino acids and a ﬂuorometric reporter at
their C-terminal end. These ﬂuorogenic substrates are cleaved by the
proteolytic activities, and the ﬂuorometric reporter, mainly a 7-amino-
4-methyl-coumarin or a β-naphtylamide, is released and its ﬂuores-
cence can be determined. It is also possible to inhibit reversibly or
irreversibly the peptidase activities by several inhibitors, peptide
aldehydes (e.g. MG132), peptide boronates (e.g. MG262), β-lactone
derivatives (e.g. lactacystin), peptide vinyl sulfones (e.g. NLVS) or
peptide epoxyketones (e.g. epoxomicin) [57].
Under certain physiological states such as enhanced immune
function, the β1-, β2- and β5-subunits can be replaced upon
interferon-γ signaling by inducible immunoforms named β1i-, β2i-
and β5i-subunits [54]. The replacement results in the formation of
“immunoproteasomes”, which favor the generation of MHC class I
antigenic peptides [58]. A recent study showed that these inducible
immunoforms can exist in parallel with their constitutive counter-
parts in the normal adult mouse myocardium [59]. The role of the
other four β-subunits remains at the moment elusive. They are
thought to be inactive [60], but one study proposed a novel N-terminal
nucleophile hydrolase activity for the β7-subunit [61]. The recent
identiﬁcation of protein phosphatase 2A and protein kinase A as
functional partners of the cardiac 20S proteasome [62] suggests
dynamic regulation of the proteasome function in the normal and
diseased heart.
Fig. 3. Schematic representation of the 26S proteasome. Molecular weight and function of the subunits are indicated. Abbreviations used are: Rpn, regulatory particle non-ATPase;
Rpt, regulatory particle triple-A; UBL, ubiquitin-like domains.
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The 19S regulatory complex, which is also known as PA700 (for
proteasome activator of 700 kDa), is composed of at least 19 distinct
subunits, which are distributed in a lid and in a base subcomplex.
According to the nomenclature of Finley et al. [63] the subunits are
named Rpn1–Rpn15 (regulatory particle non-ATPase) and Rpt1–Rpt6
(regulatory particle triple-A).
The lid subcomplex is composed of the subunits Rpn3, Rpn5–Rpn9,
Rpn11, Rpn12 and Rpn15, whose functions remain mostly unclear.
Rpn11 has a metalloprotease-like deubiquitinating activity and
catalyzes the deubiquitination of polyubiquitinated proteins [64,65].
Rpn4 was originally identiﬁed as a putative subunit of the lid
subcomplex, but recent studies showed that it acts as a transcription
factor regulating the expression of proteasome subunits via interac-
tion with PACE (proteasome-associated control element) sequences,
which were found in at least 32 genes encoding proteasome subunits
[66,67]. The subunit Rpn10 connects the lid and the base subcom-
plexes, and recognizes and binds polyubiquitin chains of proteins via
its ubiquitin interaction motif (UIM) element [68–70]. The two non-
ATPase subunits Rpn1 and Rpn2 bind a series of polyubiquitinated
chain receptors and are therefore thought to mediate indirect
targeting of polyubiquitinated proteins to the 19S regulatory complex
[71,72].
The subunits Rpt1–Rpt6 possess an AAA-family ATPase activity and
represent together with the subunits Rpn1, Rpn2 and Rpn13 the base
subcomplex. The six ATPase subunits form a hexameric ring, which isplaced on the top of the α-ring of the 20S proteasome [73]. The
interaction of the base and the α-ring activates the 26S proteasome
leading to an opening of the regulated gates in the α-ring [55].
Especially Rpt2 is known to be involved in controlling both substrate
access and product release from the 20S proteasome by opening the
gated pore of the 20S proteasome. Another function of the base is to
unfold the proteins and to channel them into the 20S core. The
ATPases have a chaperone-like activity, which enables them to bind
relatively non-speciﬁcally to protein surfaces and to change their
tertiary structure by utilizing ATP resulting in the unfolding of the
proteins [74,75]. In addition to its ATPase activity, Rpt5 binds directly
polyubiquitin chains [76]. Recent data showed that Rpn13 and Rpn14
are involved in the efﬁcient recognition of ubiquitinated Gcn4p, which
is a typical eukaryotic transcriptional activator [77].
1.2.3. Assembly of the 26S proteasome
A recent study proposed a multistep model for the assembly of the
human 20S proteasome [78]. In this model, the subunits α5 and α7
associate with a heterodimer consisting of two chaperone proteins,
the proteasome assembly chaperone 1 and 2 (PAC1, PAC2). The
remainingα-subunits can then polymerize and the heptamericα-ring
is formed. The β-subunits initially possess an N-terminal prosequence,
which prevents their degradation and which is removed after their
incorporation into the complex [79,80]. These β-propeptides associate
with the chaperone protein hUmp1 (human analog of ubiquitin-
mediated proteolysis), and this complex associates in turn with the
Table 2
Alterations of the UPS in cardiac disease
Disease UPS alterations References
Human heart failure ↑ ubiquitinated proteins [96–98,104]
↑ E2 (Ubc2) [110]
↑ E3 (Mdm2) [104]
↑ deubiquitinases [110]
Experimental cardiac hypertrophy
and failure induced by TAC
↑ ubiquitinated proteins [97,122]
↑ E2 (UbcH2) [106]
↑ E3 (atrogin-1, MuRF1) [106]
↑ E3 (Cb1, cIAPs, Mdm2) [122]
↑ proteasome subunits [105,106]
↓ or ↑ proteasome activities [97,105]
Experimental myocardial ischemia ↑ ubiquitinated proteins [99]
↓ proteasome activities [99]
Modiﬁcations of 20S subunits [99]
Experimental cardiac atrophy induced
by heterotopic heart transplantation
↑ ubiquitinated proteins [100]
↑ E2 (UbcH2) [100]
↓ E3 (atrogin-1, MuRF1) [106,112]
Doxorubicin-induced cardiomyopathy ↑ E3 (atrogin-1) [111]
↑ proteasome activities [95]
Experimental hyperglycemia ↑ ubiquitinated proteins [101]
↓ 26S proteasome activities [101]
↑ 11S subunit of the proteasome [101]
FHC cell model (truncated cMyBP-C) ↓ truncated cMyBP-C level in
cardiomyocytes; impaired UPS
[90]
DRM mouse models
(CryABR120G or mutant desmin)
↑ ubiquitinated proteins [102,103]
↑ proteasome activities [102,103]
↑ 20S subunits [102,103]
↓ 19S subunits [102,103]
Abbreviations used are: cIAPs, cellular inhibitors of apoptosis; CryAB, αB-crystallin;
cMyBP-C, cardiac myosin-binding protein C; DRM, desmin-related myopathy; E2,
ubiquitin-conjugating enzyme; E3, ubiquitin ligase FHC, familial hypertrophic
cardiomyopathy; TAC, transverse aortic constriction.
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inactive half-proteasomes dimerize and hUmp1 catalyzes the cleavage
of the prosequences of the β-subunits resulting in a 20S proteasome
with active proteolytic sites [81,82]. The prosequences, hUmp1 and
the PAC1:PAC2 heterodimer are then released and degraded by the
20S proteasome.
Only rare information exists about the assembly of the 19S
regulatory complex. A study suggests that the six ATPase subunits
(Rpt1–Rpt6) ﬁrst form the hexameric ring and then, after coupling
with Rpn1 and Rpn2, associate with the 20S proteasome [83]. Like
already mentioned above, the subunits β1, β2 and β5 can be replaced
by their inducible immunoforms resulting in an altered composition
of the 20S proteasome. In addition, various endogenous post-
translational modiﬁcations, like N-terminal myristoylation, N-term-
inal acetylation and phosphorylation of the proteasome subunits can
occur, which were shown to alter the function of the 26S proteasome
[59,62,84,85]. A recent report provides evidence of distinct protea-
some subpopulations with different activities in murine hearts [86].
The alteration in proteasome subunit composition would afford
speciﬁcity and selectivity for various protein substrates and could
therefore play a major role in the regulation of protein degradation.
1.3. Investigation of the ubiquitin–proteasome system
The UPS function can be evaluated at the step of both ubiquitina-
tion and degradation by determining the steady-state levels of
ubiquitinated proteins by Western blot and the chymotrypsin-like,
trypsin-like, and caspase-like activities of the 26S proteasomes using
speciﬁc synthetic ﬂuorogenic substrates, respectively. These small
ﬂuorogenic substrates can easily enter the 20S proteolytic core in an
ubiquitination-independent manner. However, they can also be
cleaved by non-proteasomal peptidases such as calpain and do not
reﬂect the highly-regulated entry of substances into the 20S
proteasome. In addition, although both 20S and 26S proteasomes
exist in cells, only the 26S proteasome has been proven to play a
signiﬁcant role in protein degradation. The 26S is an ATP-dependent
degradation system, whereas the 20S functions independently of ATP
[87]. Therefore, activities measured in the absence of ATP do not
accurately reﬂect the proteasome function. To better evaluate the UPS
proteolytic function in vitro or in the whole animal, a series of
ﬂuorescent protein reporters were developed [88,89]. Fluorescent
protein reporters were modiﬁed in a way that they were targeted for
ubiquitination and degradation by the UPS. These reporters use
different ubiquitination signals, such as, modiﬁed ubiquitin (Ub)
covalently linked to green/red ﬂuorescent protein (e.g., UbG76V-GFP or
UbG76V-DsRed) [88,90], a cleavable Ub fusion peptide that allows
creation of an N-end rule substrate (e.g., Ub-Arg-GFP), and the CL1
degron (GFPu) [91–93]. GFP reporter transgenic mouse models of UPS
proteolytic function have been created [94,95]. These mice are
important tools to decipher the role of the UPS in the whole animal
in various pathologies including cardiac disease.
2. Role of the ubiquitin–proteasome system in cardiac disease
A large body of evidence indicate UPS alterations in human or
experimental cardiac disease. Whereas accumulation of ubiquitinated
proteins is a common feature of cardiac disease and suggests UPS
impairment [96–104], the activities of the proteasome are not
consistently depressed in affected hearts [95,97,99,101–109]. Simi-
larly, the expression of the UPS components such as E2 conjugating-
enzymes, E3 ubiquitin ligases, or subunits of the proteasome are either
increased [100–104,106,110,111] or decreased [102,103,106,112] in
cardiac disease. On the other hand, recent studies suggest that the
muscle-speciﬁc E3 ligases play a key role in the regulation of both
cardiomyocyte and cardiac hypertrophy [13,17,30,31,33,35,113,114]. A
summary of the literature is given in Table 2 and Fig. 4.2.1. Cardiac hypertrophy and failure
Cardiac hypertrophy occurs as an adaptive response to increased
workload to maintain cardiac function in response to physiological or
pathological stress. While physiological hypertrophy can result from
exercise, pathological hypertrophy responds to events such as volume
or pressure overload, ischemia, or genetic abnormalities. Prolonged
pathologic cardiac hypertrophy causes heart failure, and its mechan-
isms are largely unknown. Cardiac remodeling during hypertrophy
and failure involves global increase in gene expression, including re-
expression of fetal genes such as β-MHC and α-skeletal actin, or up-
regulation of the expression of atrial/brain natriuretic factors [115–
117]. One key element of cardiac hypertrophy is an adaptation in
protein turnover. It refers to both protein synthesis and degradation,
and interestingly, while synthesis has always been shown to be
stimulated, protein degradation was either accelerated or unchanged
in hypertrophic hearts, but inhibited by induction of cardiac work or
high aortic pressure in Langendorff preparations [118,119]. More
recently, accumulation of ubiquitinated proteins has been reported
in human heart failure [96–98,104] suggesting impaired UPS. In an
experimental mouse model of heart failure induced by transverse
aortic constriction (TAC) both increased steady-state levels of
ubiquitinated proteins and depression of proteasome activities [97]
as well as prolongation of endoplasmic reticulum (ER) stress charac-
terized by accumulation of ER chaperones [120] were described.
Recent data also showed that the transcription factor p53 accumulates
during the transition from cardiac hypertrophy to heart failure [121].
These lines of evidence are consistentwith thehypothesis that removal
of abnormal proteins by the proteasome is insufﬁcient in heart failure.
However, depressedUPSwas not detected consistently and recent data
rather showed an activation of the UPS, including increased levels of
UPS components and proteasome activities in murine, canine and
feline models of TAC-induced cardiac hypertrophy [105,122].
A recent series of data indicate that several muscle-speciﬁc E3
ligases protect against development of cardiomyocyte hypertrophy
Fig. 4. Muscle-speciﬁc E3 ligases blunt development of experimental cardiomyocyte and cardiac hypertrophy. (A) Overexpression of atrogin-1, MuRF1 and Mdm2 prevent
development of cardiomyocyte hypertrophy induced by phenylephrine (PE) or endothelin-1 (ET-1). (B) Overexpression of MuRF1 blunts cardiac hypertrophy induced by transverse
aortic constriction (TAC) in mice. Overexpression of atrogin-1 blocks both TAC-induced pathological hypertrophy and physiological hypertrophy induced by 2 week-treatment of IGF-
1 and growth hormone (GH) in mice. Mice deﬁcient in atrogin-1 gene develop exaggerated cardiac hypertrophy in response to voluntary running exercise. Mice deﬁcient in MuRF3
gene exhibit a massive cardiac hypertrophy after myocardial infarction (MI). Adapted from [13,17,30,31,33,35,113,114].
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trophy in the whole animal. Adenoviral overexpression of atrogin-1,
MuRF1 or Mdm2 inhibits phenylephrine or endothelin-1-induced
hypertrophy in cardiomyocytes (Fig. 4A), whereas knock-down of
atrogin-1 enhanced it [13,31,113]. Similarly, the overexpression of
atrogin-1 in the heart of transgenic mice blunts both physiological
hypertrophy induced by IGF-1 and growth hormone (GH) and
pathological hypertrophy induced by TAC (Fig. 4B) [13]. Conversely,
whereas atrogin-1 knock-out (KO) mice do not exhibit any cardiacphenotype under basal conditions, they develop marked physiological
cardiac hypertrophy in response to voluntary running exercise (Fig.
4B) [17]. These data support the view that atrogin-1 regulates both
physiological and pathological hypertrophy. On the one hand, atrogin-
1 disrupts the Akt pathway by activating (by ubiquitinating) FoxO1/
FoxO3 through the addition of “non-canonical” K63-linked chains
[17]. On the other hand, atrogin-1 blocks hypertrophy by ubiquitinat-
ing and degrading calcineurin via the “canonical” K48-linked chains
and therefore prevents nuclear translocation of the transcription
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either MuRF1, MuRF2 or MuRF3 gene do not show signs of cardiac
hypertrophy under basal conditions [30,33,114]. However, while
MuRF1 KO mice develop exaggerated hypertrophy after TAC [114],
MuRF3 KO mice develop cardiac rupture after myocardial infarction
(Fig. 4B) [17]. Other evidence indicate that MuRF1 is a key regulator of
the PKC-dependent hypertrophic response [31], while MuRF3 plays a
key role in maintaining ventricular integrity after myocardial infarc-
tion by stimulating the turnover of FHL2 and γ-ﬁlamin [33].
Interestingly, the double MuRF1/MuRF2 KO mice develop a severe
phenotype quickly after birth, and most of them die from chronic
heart insufﬁciency and acute cardiac decompensation with heart
failure [30]. Similarly, the double MuRF1/MuRF3 KO mice develop an
extreme and lifelong muscle hypertrophy [35]. This demonstrates the
cooperativity between MuRF1 and MuRF2 and between MuRF1 and
MuRF3 at the genetic level. In contrast to MuRF1-KO and atrogin-1-
KO, which do not develop a cardiac phenotype in the basal conditions,
the cardiomyocyte-speciﬁc VHL-KO develop severe progressive
structure degeneration and heart failure, malignant transformation
and premature death by chronic activation of the HIF-1α hypoxia
response pathway [123]. These data strongly support that VHL is
required for normal cardiac structure and function and that HIF-1α is
central to this role of VHL.
2.2. Myocardial ischemia
Recent observations suggest that UPS impairment contributes to
the pathophysiology of myocardial ischemia. The ﬁrst evidence
indicate loss of the 20S trypsin-like activity after 30 min of in vivo
left anterior descending (LAD) occlusion [107]. Loss of activity was
associated with oxidative modiﬁcations (4-hydroxy-nonenalyation,
4-HNE) of several proteasome subunits and accumulation of ubiqui-
tinated proteins. These data were then conﬁrmed in isolated perfused
heart and indicate that not only the 20S activities were decreased but
also the 26S activities, which was consistent with increased steady-
state levels of ubiquitinated proteins [99]. The mechanism by which
UPS dysfunction is induced during ischemia is not clear. The degree of
proteasome inhibition depends on the duration of ischemia, and
recent data showed that pretreatment of isolated hearts with the
proteasome inhibitor lactacystin results in higher accumulation of
oxidized proteins and decreased degradation of oxidized actin in the
postischemic heart [124]. It was recently demonstrated that the 19S
ATPase subunit Rpt6 is very sensitive to oxidative inactivation [125].
Moreover, modiﬁcation of the 20S subunits by 4-HNE results in
speciﬁc changes in 2D electrophoresis pattern associated with
reduced 20S proteasomal activity [108].
A recent series of data indicate that muscle-speciﬁc E3 ligases play
a key role in myocardial ischemia. Both CHIP and Mdm2 have been
shown to modulate apoptosis and severity of disease in ischemia/
reperfusion injury [36,113]. CHIP KO mice are much more sensitive to
ischemia/reperfusion injury thanwild-type mice [36], suggesting that
CHIP is cardioprotective. The mechanism of cardioprotection may be
related to the ability of CHIP to bind damaged proteins in association
with the chaperones Hsp70 and Hsp90, and therefore to coordinate
their refolding or to mediate their degradation via its E3 ligase activity.
The transcription factor p53 is an important effector of ischemia/
reperfusion. Interestingly, the E3 ligase Mdm2 binds to p53 and
inhibits its transcriptional activity but also acts as a E3 ubiquitin ligase
by promoting ubiquitination and proteasomal degradation of p53
[44,126].
2.3. Cardiac atrophy
Atrophy is characterized by a change in the balance of protein
turnover toward proteolysis. Previous studies in skeletal muscle
atrophy induced by different means have shown increased mRNAlevels for ubiquitin, E2 ubiquitin-conjugating enzymes, E3 ubiquitin
ligases such as atrogin-1 and MuRF1, and components of the
proteasome, indicating UPS activation [127,128]. Much less is known
about the UPS in cardiac atrophy, likely because this state is
physiologically less relevant. However, unloading the heart with a
left ventricular assist system is used in clinical practice for patients
waiting for heart transplantation. Mechanical unloading of the heart
can be experimentally induced in animals by heterotopic heart
transplantation. This results in atrophic remodeling with reactivation
of a “fetal gene program”, such as observed in cardiac hypertrophy
[129]. The recent demonstration of increased steady-state levels of
ubiquitinated proteins, increased mRNA levels of the ubiquitin-
conjugating enzyme UbcH2 and of downstream targets of mTOR
supports the view of simultaneous activation of protein synthesis and
UPS-mediated degradation in this model [100,106,112]. However, and
in contrast to skeletal muscle atrophy, mRNA levels of atrogin-1 and
MuRF1 decreased in cardiac atrophy [106,112].
2.4. Other cardiac diseases
Doxorubicin, a potent anti-cancer agent of the anthracycline family
induced cardiomyopathy. Recent evidence indicate that doxorubicin
increases both the atrogin-1 mRNA levels in cardiac myocytes [111]
and the UPS function in GFPdgn reporter mice [95], suggesting that
UPS activation may contribute to acute cardiotoxicity of doxorubicin
therapy.
Hyperglycemia is an independent risk factor for diabetic heart
failure. However, the mechanisms by which hyperglycemia induced
cardiac damage remain poorly understood. Recent studies showed
that the UPS becomes dysfunctional [101] and that the transcription
factor GATA4 is down-regulated via the activation of its E3 ligase CHIP
during experimental hyperglycemia [130]. These studies suggest that
UPS alterations may also be involved in human diabetic heart failure.
2.5. Familial cardiomyopathies
Recent studies suggest that UPS alterations might play a role in
familial cardiomyopathies, namely in familial hypertrophic cardio-
myopathy (FHC) and desmin-related cardiomyopathy (DRM).
2.5.1. Familial hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is recognized on the basis of
the most striking features of the condition — asymmetric septal
hypertrophy, left ventricular outﬂow tract obstruction and premature
sudden death. The disease prevalence has been estimated at
approximately 1:500 in young adults [131]. HCM is the major cause
of sudden death in young adults and particularly young athletes and is
associated with a signiﬁcantly increased risk of heart failure and
malignant arrhythmia. HCM is associated with myocardial and
myoﬁbrillar disarray. Ultrastructural analysis of hypertrophied ven-
tricular tissue from patients with HCM showed a degeneration of
cardiomyocytes [132]. Particularly, diseased myocytes exhibited a
variety of ultrastructural alterations, such as myoﬁbrillar lysis or
marked development of the sarcoplasmic reticulumandmitochondria.
HCM is an autosomal-dominant familial disease (FHC) in most of
the cases [133]. The typical forms of the disease involvemore than 400
different mutations in at least 13 genes encoding sarcomeric proteins
(for reviews, see [134,135]). Out of them, MYBPC3 is one of the most
frequently mutated genes [136]. It encodes cardiac myosin-binding
protein C (cMyBP-C) [137,138], which is a major component of the
thick ﬁlament and only expressed in the heart in mammals [139,140].
cMyBP-C has both structural and regulatory roles in cardiac muscle
[138]. Recent data using cMyBP-C KO cardiomyocytes or tissue
demonstrated that cMyBP-C participates in the decreased Ca2+
sensitivity of the myoﬁlament under β-adrenergic stimulation [141],
is necessary for complete relaxation in diastole [142], and modulates
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MYBPC3 mutations result in a frameshift and should produce
truncated cMyBP-C [144]. However, truncated cMyBP-C proteins
were not detected in myocardial tissue of two unrelated FHC patients
with frameshift mutations [145,146], suggesting haploinsufﬁciency as
a disease mechanism. Interestingly, heterozygous cMyBP-C KO mice
carrying only one functional allele exhibit the key feature of human
FHC that is asymmetric septal hypertrophy [147], which is preceded by
gene expression changes including activation of the JNK and p38 parts
of the MAPK pathway and induction of apoptosis [148]. Overexpres-
sion of human truncated cMyBP-Cs in cardiomyocytes or transgenic
mice showed markedly less expression than the wild-type protein
[90,149,150]. The absence of biomolecular interaction between
truncated cMyBP-C and human β-MHC [151] suggests that lack of
sarcomeric incorporation may be one of the mechanisms by which
degradation of truncated cMyBP-C is promoted. This is supported by
data showing that sarcomeric disassembly precedes degradation of
cardiac MHC [152]. Truncated cMyBP-Cs have been shown to be
rapidly and quantitatively degraded by the UPS and to a lower extent
by the lysosome after adenoviral gene transfer in cardiomyocytes
using speciﬁc inhibitors of both pathways [90]. The formation of
ubiquitin-positive aggregates of truncated cMyBP-C and accumulation
of the ﬂuorescent UPS reporter UbG76V-DsRed in the presence of
mutant, but not thewild-type cMyBP-C strongly suggest impaired UPS
by the truncated cMyBP-C [90]. The mechanism by which the UPS is
impaired is not elucidated yet. However, it is tempting to hypothesize
that cMyBP-C mutants compete with other degradation-prone
proteins for the UPS. This could result in accumulation of factors
such as hypertrophic or apoptotic factors that can directly or indirectly
lead to hypertrophy. Further analyses are needed to investigate such
impairment in vivo.
2.5.2. Familial dilated cardiomyopathy
The role of the UPS may also be seen in familial dilated
cardiomyopathies (F-DCM). DCM is characterized by left ventricular
dilation and systolic dysfunction. The incidence has been evaluated at
3.5–8.5/100000 individuals/year. It is the major cause of heart failure
and heart transplantation [153]. Several inheritance forms have been
identiﬁed, but themost common form is transmitted as an autosomal-
dominant trait. In the pure form of F-DCM, 11 genes have been
identiﬁed encoding different components of cardiomyocytes, includ-
ing sarcomeric proteins, lamin A/C, and cytoskeletal proteins such as
αB-crystallin (CryAB) and desmin (for detailed review, see [135]).
Desmin aggregates have also been frequently found in human heart
failure [154]. Experimentally, involvement of the UPS in F-DCM has
been mainly evidenced in desmin-related myopathy (DRM), which
was initially characterized by marked accumulation of desmin in
skeletal and cardiac muscle and transmitted in an autosomal-
dominant fashion [155]. The same group identiﬁed 10 years later the
corresponding R120G mutation in the gene encoding CryAB [156].
CryAB is the most abundant heat shock protein in the heart.
Transgenic mice expressing a CryABR120G mutant develop cardiomyo-
pathy at 3 months and die at 6–7 months from heart failure [157].
These mice show perinuclear aggregates containing both desmin and
preamyloid oligomer [158], suggesting that CryAB-DRM is a subclass
of the aggresomal and amyloid-related neurodegenerative disorders
such as Alzheimer's and Parkinson's diseases [159]. The cross between
CryABR120G mutant transgenic mice with the GFPdgn reporter mice
revealed marked UPS impairment and accumulation of aggregates
[102]. Interestingly, recent data demonstrated that voluntary exercise
slows the progression to heart failure and reduced preamyloid
aggregates formation in CryABR120G mice [160]. Similar UPS impair-
ment was found in another DRM mouse model associated with a
desmin mutation [103,161]. The molecular mechanisms by which
aggregates impair the UPS remain elusive. It has been proposed that
aggregated proteins themselves directly inhibit the 26S proteasomeby “chocking” the proteases. Alternatively protein aggregates may
indirectly interfere with UPS function by inactivating or depleting UPS
components. Data obtained byWang and collaborators indeed suggest
a diminished entry of ubiquitinated protein into the 20S proteasome,
likely due to depletion of key components of the 19S proteasomes
[102,103,161].
3. Effect of proteasome inhibitors on cardiac function
Short term proteasome inhibition during ischemia/reperfusion
injury and cardiac hypertrophy results in cardioprotection and cardiac
hypertrophy regression in vivo. However, recent studies have
demonstrated that proteasome inhibition therapy can result in
signiﬁcant cardiac side effects. In humans given Velcade® for the
treatment of multiple myeloma, unexpected increases in cardiac
complications have been described. The therapeutic value of protea-
some inhibition in cardiac disease in humans has not been tested to
date.
3.1. Proteasome inhibition in cardiac hypertrophy
The development of cardiac hypertrophy depends on the function
of the proteasome. Initial studies identiﬁed that NF-κB activity is
essential in the development of hypertrophy, a process that is
dependent on the proteasome-dependent degradation of the multi-
meric inhibitor of κB (IκB). When the hypertrophy driven activation of
NF-κB is inhibited experimentally, agonist-induced cardiomyocyte
hypertrophy is prevented [162]. Knowing that NF-κB is critical in the
hypertrophic growth of cardiomyocytes, additional studies were
performed using NF-κB inhibitors. Similarly, in vivo inhibition of NF-
κB attenuates cardiac hypertrophy development [163,164]. During the
course of NF-κB activation, IκB is phosphorylated, and subsequently
degraded, releasing NF-κB to the nucleus. The phosphorylated IκBα
subunit is recognized speciﬁcally by the E3 ubiquitin ligase Skp-
Cullin-F-box β-transducin repeat-containing protein (SCF-βTrCP),
which ubiquitinates it for degradation by the proteasome.
Knowing that NF-κB activation is dependent on proteasome
activity, it was next determined if a broader inhibition of the
proteasome could inhibit cardiac hypertrophy, by inhibiting NF-κB
among other mechanisms. Indeed, partial inhibition of the protea-
some suppresses the hypertrophic growth of neonatal rat cardiomyo-
cytes in culture [165]. Inhibition of hypertensive Dahl-salt sensitive
rats with the proteasome inhibitor Velcade® signiﬁcantly similarly
reduces cardiac hypertrophy, providing support for the therapeutic
possibility of using low-dose proteasome inhibition as a therapy to
interrupt the development of cardiac hypertrophy [165]. Recent
studies have extended these ﬁndings, using experimental proteasome
inhibitors to prevent not only the induction of hypertrophy, but also to
induce the regression of established cardiac hypertrophy [166]. The
ability of proteasome inhibition to prevent left ventricular hypertro-
phy development and promotion of its regression suggests that it may
be useful clinically, but remains currently untested.
3.2. Proteasome inhibition in ischemia/reperfusion injury in the heart
When the 26S proteasome is experimentally inhibited before
cardiac ischemia/reperfusion injury, a signiﬁcant reduction in cardiac
infarct size and concomitant left ventricular function occurs [167–
172]. This transient inhibition of the proteasome may be cardiopro-
tective by several mechanisms, including the induction of heat shock
proteins and the inhibition of NF-κB activity [169–171,173]. Protea-
some inhibition after the induction of experimental ischemic events
inhibits ventricular triplets, which are highly predictive of sudden
cardiac death during the ﬁrst 24 h after bortezomib treatment [174].
Malignant tachyarrthymias and sudden cardiac death are hypothe-
sized to be suppressed through the inhibition of G-protein signaling
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endogenously during ischemic injury. A recent study demonstrated
that phosphorylated IκB accumulates after ischemic injury, indicating
deﬁcit proteasome activity [109]. However, other proteasome func-
tions were intact, suggesting that a more speciﬁc proteasome
inhibition occurs during ischemic injury, in contrast to the more
global pharmacologic inhibition that occurs experimentally [109].
3.3. Chronic proteasome inhibition in cardiac hypertrophy
In contrast to the studies described above investigating the short
term beneﬁcial effects of proteasome inhibition, chronic inhibition of
the cardiac proteasome may be detrimental. Bortezomib is approved
by the FDA for the therapy of multiple myeloma, and its most common
side effects include neurological symptoms and thrombocytopenia
[176]. An unexpected increase in cardiac complications has been
identiﬁed ranging from arrhythmias to heart failure [177]. In this study
of 69 patients, 10% experienced cardiotoxicity and were generallyFig. 5. FoxO3 transcriptionally regulates both the autophagy–lysosomal pathway and key E3 u
regulation of cardiac hypertrophy. (A) Upon external stimuli such as ischemia, autophagy is
double membrane vesicle occurs by a coordinated process involving numerous proteins such
with the lysosome, autophagosomes are degraded by lysosomal proteases. FoxO3 transcr
(E) FoxO3 regulates the expression of E3 ubiquitin ligase (e.g. atrogin-1), which is pivotal
digested substrates. Adapted from [13,14,17,196].N60 years old and received a cumulative dose of at least 20.8 mg/m2
[177]. Asymptomatic arrhythmia following bortezomib therapy has
also been reported [178]. It is still unknown the mechanism by which
bortezomib is cardiotoxic. However, there is currently a clear
dichotomy between the beneﬁts of short term bortezomib use in
cardiac disease, and its cardiotoxicity seen after longer term use.
4. Role of autophagy in cardiac disease
A recent series of studies have outlined the parallel regulation of
autophagy and the UPS, which may act in concert to regulate the
necessary turnover of proteins. The process of autophagy involves the
degradation of cytosolic components within lysosomes [179–183]. It
occurs continuously to repair cellular components to maintain
homeostasis, during both health and disease as a way to regulate
protein quality control. Importantly, by degrading endogenous
proteins, autophagy also supplies nutrients for survival during times
of stress [184,185]. Cardiac autophagy was ﬁrst described in culturedbiquitin ligases (i.e. atrogin-1) involved in the UPS-mediated degradation and therefore
induced in cardiomyocytes. (B) Sequestering of cytosolic organelles and proteins by a
as Bnip3 and LC3. (C) The autophagosome fuses with a lysosome. (D) Following fusion
iptionally regulates proteins essential in autophagosome formation (Bnip3 and LC3).
in degrading substrates (e.g. calcineurin, CnA) by the UPS. Peptides correspond to the
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identiﬁed autophagic vesicles containing damaged organelles in
cells within 24 h of culture [186]. Increased autophagy has
subsequently been described in a wide range of cardiac disease states,
including cardiomyopathy, heart failure, ischemic injury, but not in
normal heart [110,123,187–191]. While autophagy is an ongoing
process in baseline conditions, it may be more apparent in disease
because it is signiﬁcantly up-regulated in response to hemodynamic
stress [192].
Cardiomyocytes with deﬁcient autophagy have increased levels
of ubiquitinated proteins in autophagosomes, indicating that
autophagy may work in parallel with the UPS to turnover cellular
proteins. The process of autophagy involves numerous proteins,
including ubiquitin-like proteins (e.g. Atg5 and Atg8), which
participate in the formation of autophagosome vesicles (for a
more complete review, see [193]). In mice lacking cardiac Atg5,
autophagy is inhibited, resulting in cardiac hypertrophy, dilation,
and contractile dysfunction [192]. Hearts from Atg5 deﬁcient mice
have increased levels of ubiquitinated proteins, disorganized
sarcomeres, and mitochondrial aggregation [192]. These ﬁndings
suggest a key role of UPS in the maintenance of essential cardiac
structures that preserve contractility and energy production in the
process of autophagy. While the presence of ubiquitinated cyto-
plasmic inclusions is a feature of cardiomyocytes during autophagy,
the relationship between the proteasome and the degradation of
these proteins is unclear in the process of autophagy. A ﬁnal parallel
between the UPS and the process of autophagy is their regulation.
Recent studies demonstrated that the transcription factor FoxO3 is
required for the induction of autophagy in skeletal muscle,
regulating several autophagy-related genes such as LC3 (micro-
tubule-associated protein 1 light chain 3) and Bnip3 (Bcl-2/
adenovirus E1B 19 kDa-interacting protein) [194]. Similarly, it has
been shown that the transcription factor HIF-1α, which is down-
regulated by the UPS, also activates Bnip3 and the process of
autophagy in the heart [123].
Cardiac FoxO3 inhibits cardiac hypertrophy by activating the
transcription of E3 ubiquitin ligases such as atrogin-1 or MuRF1
[195], which themselves prevent cardiac hypertrophy [13,17,114].
Interestingly, a recent study demonstrated that FoxO3 coordinately
regulates degradation by autophagy and the UPS (Fig. 5) [196]. Further
studies are needed to evaluate whether similar parallel regulation of
autophagy and UPS exist in cardiomyocytes and in the whole animal.
5. Conclusion and future directions
The involvement of the UPS in the regulation of normal and
pathological cardiac structure and function is now clearly established.
However, whereas accumulation of ubiquitinated proteins is a
common feature of cardiac dysfunction and suggests UPS impairment,
the proteasome activities measured with ﬂuorogenic substrates are
not consistently depressed in affected hearts. The recent development
of a series of UPS reporter adenovirus or mice has opened the way to
better investigate the global function of the system in vivo. In addition,
our understanding of the molecular mechanisms involved in UPS-
mediated degradation in healthy and diseased heart is just at the
beginning. A series of recent evidence underlined the key role of the
muscle-speciﬁc E3 ubiquitin ligases in blunting the development of
physiological and pathological cardiac hypertrophy. Knowing that the
E3 ligases give the speciﬁcity to the system, we expect that other
cardiac-speciﬁc E3 ligases will be identiﬁed in the future providing
additional molecular mechanisms and signaling pathways. Although
short term and/or low doses or proteasome inhibition prevents left
ventricular hypertrophy in animal models, chronic use in human
treated with bortezomib is not without cardiotoxicity. Finally, the
identiﬁcation of the FoxO3 transcription factor coordinating the
lysosomal and nonlysosomal pathways for degradation opens newperspectives of research and potential novel therapies for cardiac
diseases.
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